Andromedic at ESHO 2026
Andromedic will participate in ESHO 2026, the 37th Annual Meeting of the European Society for Hyperthermic Oncology, which will take place in Erlangen, Germany. An important international event dedicated to research, innovation, and clinical applications of oncological hyperthermia. During the event, we will showcase HY-DEEP 600WM, our deep oncological hyperthermia system based on radiofrequency technology. It will be a valuable opportunity to exchange knowledge and insights with physicians, researchers, and international professionals committed to advancing hyperthermia in oncology.
From October 4 to 6, 2026, Andromedic will participate in ESHO 2026 – 37th Annual Meeting of the European Society for Hyperthermic Oncology, which will take place in Erlangen, Germany.
ESHO is one of the leading international events dedicated to oncological hyperthermia, bringing together specialists from various countries and disciplines, including oncologists, radiation oncologists, physicists, researchers, engineers, and companies involved in the development of hyperthermia treatment technologies.
The European Society for Hyperthermic Oncology (ESHO) promotes fundamental and applied research on the use of hyperthermia in cancer treatment and encourages the exchange of knowledge among the different disciplines involved. Particular attention is given to the study of hyperthermia and its integration with other cancer treatment modalities.
The 2026 edition will feature a scientific program focused on the latest research findings and innovative approaches in the field of hyperthermia, providing an important platform for dialogue between scientific research, clinical practice, and technological development.
Andromedic will participate in the event as an exhibitor, showcasing HY-DEEP 600WM, the system developed and manufactured by the company for deep oncological hyperthermia using capacitive radiofrequency technology at 13.56 MHz.
The presence of the device at our exhibition booth will allow attending professionals to explore the features and operation of our technology firsthand, while also creating valuable opportunities for discussions with physicians, researchers, and hyperthermia specialists from different countries.
Participation in ESHO 2026 will also represent an important opportunity for Andromedic to gain insights into the latest scientific and clinical developments in the field, engage with the international community, and strengthen relationships with professionals and organizations involved in hyperthermia research and clinical applications.
Our presence in Erlangen with HY-DEEP 600WM will reaffirm Andromedic’s commitment to contributing to technological advancements in the field and fostering collaboration between innovation, scientific research, and clinical practice, with the aim of supporting the increasing integration of hyperthermia into cancer treatment pathways.
